$IRD

2024 Q4 Form 10-Q Financial Statement

#000114036124046045 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $3.867M
YoY Change -67.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $8.982M
YoY Change 157.07%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $11.88M
YoY Change 114.02%
Operating Profit -$8.009M
YoY Change -225.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $483.0K
YoY Change 5.92%
Pretax Income -$7.526M
YoY Change -235.0%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.526M
YoY Change -235.34%
Net Earnings / Revenue -194.62%
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$0.29
COMMON SHARES
Basic Shares Outstanding 31.57M 26.20M
Diluted Shares Outstanding 26.15M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $36.60M
Short-Term Investments
Other Short-Term Assets $86.00K
YoY Change 68.63%
Inventory
Prepaid Expenses $343.0K
Receivables $1.857M
Other Receivables
Total Short-Term Assets $40.39M
YoY Change -25.47%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $40.39M
Total Long-Term Assets $0.00
Total Assets $40.39M
YoY Change -25.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $844.0K
YoY Change -55.34%
Accrued Expenses $5.171M
YoY Change 168.48%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.089M
YoY Change 55.77%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.089M
Total Long-Term Liabilities
Total Liabilities $6.089M
YoY Change 55.77%
SHAREHOLDERS EQUITY
Retained Earnings -$103.9M
YoY Change 35.47%
Common Stock $3.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.30M
YoY Change
Total Liabilities & Shareholders Equity $40.39M
YoY Change -25.47%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$7.526M
YoY Change -235.34%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11935000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6690000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
11876000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8009000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6386000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
483000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1224000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7526000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2023Q4 us-gaap Assets
Assets
53948000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
844000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2153000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5171000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6089000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4042000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81466000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34300000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40389000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10918000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13812000
us-gaap Operating Expenses
OperatingExpenses
22492000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5134000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36632000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50501000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131370000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49906000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5549000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24045000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7526000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1857000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
926000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
429000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
3000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
15000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
40389000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
53948000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2024Q3 us-gaap Assets
Assets
40389000
CY2024Q3 us-gaap Liabilities
Liabilities
6089000
CY2023Q4 us-gaap Liabilities
Liabilities
4042000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26198444
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26198444
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23977491
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23977491
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138160000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103863000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53948000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3867000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2055000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3494000
us-gaap Operating Expenses
OperatingExpenses
30735000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
456000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1648000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5575000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
74000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19817000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17358000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2894000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8680000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8982000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22397000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5177000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5561000
us-gaap Net Income Loss
NetIncomeLoss
-22397000
us-gaap Net Income Loss
NetIncomeLoss
-5191000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5561000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22397000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5191000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Concentration of Credit Risk<br/> <br/> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Management follows approved policies established by the Company’s Board of Directors (the “Board”) to reduce credit risk associated with the Company’s cash deposit and investment accounts. Pursuant to these policies, the Company limits its exposure through the kind, quality and concentration of its investments. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company’s cash and cash equivalents are held or managed by two financial institutions in the United States. </span>As of September 30, 2024, the Company had cash equivalents of $36.1 million that were not eligible for coverage by Federal Deposit Insurance Corporation<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span></span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> These balances are invested in funds whose assets consist almost entirely of securities issued by the U.S. Treasury or guaranteed by the U.S. government<span style="letter-spacing: normal; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></span><br/> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;">Derivative Liability</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separation from the underlying agreement under ASC 815 – <span style="font-style: italic;">Derivatives and Hedging</span>. An embedded derivative that requires separation is accounted for as a separate liability from the host agreement. The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value change of a separated embedded derivative at each reporting period in the statements of comprehensive (loss) income under the fair value change in derivative liability line item. The Company determined that certain features under an equity line financing (See Note 6 — Stockholders’ Equity) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying equity line financing agreement.</div>
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001228627
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34079
dei Entity Registrant Name
EntityRegistrantName
Opus Genetics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
dei City Area Code
CityAreaCode
248
dei Local Phone Number
LocalPhoneNumber
957-9024
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Ocuphire Pharma, Inc.
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IRD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31568457
CY2024Q3 ird Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
1468000
CY2023Q4 ird Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
1407000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
74000
CY2024Q3 ird Financing Costs
FinancingCosts
0
CY2023Q3 ird Financing Costs
FinancingCosts
1328000
ird Financing Costs
FinancingCosts
0
ird Financing Costs
FinancingCosts
1328000
CY2024Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-7526000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26145080
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21446648
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25501117
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21117211
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26145080
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22405995
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25501117
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21117211
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46239000
CY2023Q1 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
2000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
804000
CY2023Q1 ird Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5791000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
41250000
CY2023Q2 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
7000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1422000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4961000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
37704000
CY2023Q3 ird Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
6504000
CY2023Q3 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
60000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
573000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5561000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
50282000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49906000
CY2024Q1 ird Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
2479000
CY2024Q1 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
165000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
985000
CY2024Q1 ird Adjustments To Additional Paid In Capital Share Repurchases For Payment Of Employee Taxes
AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
42000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7106000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
46057000
CY2024Q2 ird Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
1563000
CY2024Q2 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
25000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
806000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7765000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
40636000
CY2024Q3 ird Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
455000
CY2024Q3 ird Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
41000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
776000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-7526000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34300000
us-gaap Net Income Loss
NetIncomeLoss
-22397000
us-gaap Net Income Loss
NetIncomeLoss
-5191000
us-gaap Share Based Compensation
ShareBasedCompensation
2567000
us-gaap Share Based Compensation
ShareBasedCompensation
2799000
us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
3000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-12000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-38000
ird Financing Costs
FinancingCosts
0
ird Financing Costs
FinancingCosts
1328000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
931000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8834000
ird Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
61000
ird Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
-2341000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-670000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-969000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1319000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
709000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3321000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
239000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18138000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5660000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4497000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5482000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
186000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
106000
ird Share Repurchases For Payment Of Employee Taxes
ShareRepurchasesForPaymentOfEmployeeTaxes
42000
ird Share Repurchases For Payment Of Employee Taxes
ShareRepurchasesForPaymentOfEmployeeTaxes
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4269000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5376000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13869000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-284000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50501000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42634000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36632000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42350000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
318000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
ird Unpaid Issuance Costs
UnpaidIssuanceCosts
46000
ird Unpaid Issuance Costs
UnpaidIssuanceCosts
115000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
1022000
ird Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
0
ird Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
154000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36600000
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Use of Estimates</div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 ird Cash Equivalents Not Eligible For Fdic Coverage
CashEquivalentsNotEligibleForFDICCoverage
36100000
ird Impairment On Investment
ImpairmentOnInvestment
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
ird Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ird Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
ird Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2024Q3 ird Payments Due Under Cvr Agreement
PaymentsDueUnderCVRAgreement
0
CY2024Q3 ird Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2021Q2 ird Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q3 ird Number Of Potential Milestones
NumberOfPotentialMilestones
0
ird Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
us-gaap Operating Lease Cost
OperatingLeaseCost
27000
us-gaap Operating Lease Cost
OperatingLeaseCost
27000
CY2024Q3 ird Lessee Non Cancellable Lease Liability To Be Paid One Year Or Less
LesseeNonCancellableLeaseLiabilityToBePaidOneYearOrLess
9000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
343000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
997000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
86000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
102000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
429000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q3 us-gaap Depreciation
Depreciation
1000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
0
CY2024Q3 us-gaap Depreciation
Depreciation
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
410000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
973000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2024Q3 ird Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
3725000
CY2023Q4 ird Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
400000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
63000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5171000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
776000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
573000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2567000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2799000
CY2024Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
0
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
81234
ird Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.01
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
0
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
72986
ird Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2024Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
245000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
275000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y7M6D
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26145080
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21446648
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25501117
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21117211
CY2024Q3 ird Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
CY2023Q3 ird Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
914583
ird Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
ird Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
CY2024Q3 ird Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
CY2023Q3 ird Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
44764
ird Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
ird Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
CY2024Q3 ird Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
CY2023Q3 ird Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
ird Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
ird Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26145080
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22405995
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25501117
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21117211
ird Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
ird Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-046045-index-headers.html Edgar Link pending
0001140361-24-046045-index.html Edgar Link pending
0001140361-24-046045.txt Edgar Link pending
0001140361-24-046045-xbrl.zip Edgar Link pending
ef20034582_10q.htm Edgar Link pending
ef20034582_ex10-1.htm Edgar Link pending
ef20034582_ex10-2.htm Edgar Link pending
ef20034582_ex10-3.htm Edgar Link pending
ef20034582_ex31-1.htm Edgar Link pending
ef20034582_ex31-2.htm Edgar Link pending
ef20034582_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ird-20240930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ird-20240930_cal.xml Edgar Link unprocessable
ird-20240930_def.xml Edgar Link unprocessable
ef20034582_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
ird-20240930_lab.xml Edgar Link unprocessable
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ird-20240930_pre.xml Edgar Link unprocessable